[Development of memory-like CAR-NK cells with durable antitumor activity].

Recent advancements and persisting challenges in the evolution of next generation car t cell therapy for solid malignancies: a comprehensive review

In vivo CAR‑T therapy: recent progress and future directions

In vivo CAR-T is poised to broaden the reach of cellular immunotherapy, provided that its development is guided by rigorous pharmacology, chemistry, manufacturing and controls, and long-term molecular safety surveillance.

Umbilical cord blood-derived CAR-NK cells: an emerging off-the-shelf platform for cancer immunotherapy.

Relapses occurring within 2 to 3 months correlated with loss of detectable CAR-NK cells, highlighting limited in vivo persistence as a principal barrier to durable response.

Precision targeting and alternative effector cells: Revolutionizing CAR-based therapy for T-cell malignancies.

29 Engineering CD16-Enhanced Stem Cell–Derived Universal NKT Cells to Potentiate Anti-CD70 Therapy in Renal Cell Carcinoma

CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...

Functional Exhaustion Limits CAR-NK Therapy in Glioblastoma but Can Be Mitigated by Early Repeated Dosing

Abstract With the commercial success of Chimeric Antigen Receptor T (CAR-T) cell therapies in the blood cancer setting, there are increasing numbers of clinical trials evaluating this treatment modality in patients with solid tumors, including brain tumors. Allogeneic CAR-natural killer (NK) cell therapy offers an attr...